Review Article | Published:

Beyond gut feelings: how the gut microbiota regulates blood pressure

Nature Reviews Cardiology volume 15, pages 2032 (2018) | Download Citation

Abstract

Hypertension is the leading risk factor for heart disease and stroke, and is estimated to cause 9.4 million deaths globally every year. The pathogenesis of hypertension is complex, but lifestyle factors such as diet are important contributors to the disease. High dietary intake of fruit and vegetables is associated with reduced blood pressure and lower cardiovascular mortality. A critical relationship between dietary intake and the composition of the gut microbiota has been described in the literature, and a growing body of evidence supports the role of the gut microbiota in the regulation of blood pressure. In this Review, we describe the mechanisms by which the gut microbiota and its metabolites, including short-chain fatty acids, trimethylamine N-oxide, and lipopolysaccharides, act on downstream cellular targets to prevent or contribute to the pathogenesis of hypertension. These effects have a direct influence on tissues such as the kidney, the endothelium, and the heart. Finally, we consider the role of the gut microbiota in resistant hypertension, the possible intergenerational effect of the gut microbiota on blood pressure regulation, and the promising therapeutic potential of gut microbiota modification to improve health and prevent disease.

Key points

  • High dietary intake of fruit, vegetables, and fibre is associated with lower blood pressure levels

  • Short-chain fatty acids, such as acetate and propionate, released by the fermentation of fibre by the gut microbiota are linked to lower blood-pressure levels in experimental models of hypertension

  • A growing body of literature supports a role for the gut microbiota in the development and maintenance of high blood-pressure levels

  • Limited evidence suggests that the manipulation of the gut microbiota (such as through faecal transplants, or the use of antibiotics or probiotics) might be a novel therapeutic approach for the treatment of hypertension

  • The composition of human gut microbiota in the setting of high blood-pressure levels should be assessed to determine the complex nature of essential hypertension, given that gut microbiota can interact with the the host's environment and genome

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat. Genet. 48, 1151–1161 (2016).

  2. 2.

    et al. Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci. Nat. Genet. 48, 1162–1170 (2016).

  3. 3.

    et al. The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nat. Genet. 48, 1171–1184 (2016).

  4. 4.

    & Behavioral and dietary risk factors for noncommunicable diseases. N. Engl. J. Med. 369, 954–964 (2013).

  5. 5.

    et al. Relationship of physical activity and body mass index to the risk of hypertension: a prospective study in Finland. Hypertension 43, 25–30 (2004).

  6. 6.

    & The contributory role of gut microbiota in cardiovascular disease. J. Clin. Invest. 124, 4204–4211 (2014).

  7. 7.

    et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282–1286 (2009).

  8. 8.

    et al. High fibre diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in DOCA-salt hypertensive mice. Circulation (2017).

  9. 9.

    et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262–266 (2015).

  10. 10.

    et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, 1027–1031 (2006).

  11. 11.

    & Gut–brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 36, 305–312 (2013).

  12. 12.

    , & Genomics of schizophrenia: time to consider the gut microbiome? Mol. Psychiatry 19, 1252–1257 (2014).

  13. 13.

    et al. Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. Nat. Commun. 6, 7320 (2015).

  14. 14.

    , & Diet, metabolites, and “western-lifestyle” inflammatory diseases. Immunity 40, 833–842 (2014).

  15. 15.

    , , & Role of the gut microbiota in immunity and inflammatory disease. Nat. Rev. Immunol. 13, 321–335 (2013).

  16. 16.

    et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565–569 (2016).

  17. 17.

    , & Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14, e1002533 (2016).

  18. 18.

    , , & More than 9,000,000 unique genes in human gut bacterial community: estimating gene numbers inside a human body. PLoS ONE 4, e6074 (2009).

  19. 19.

    et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 32, 834–841 (2014).

  20. 20.

    et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).

  21. 21.

    et al. Comparative metagenomics of microbial communities. Science 308, 554–557 (2005).

  22. 22.

    & Diet, gut microbiota and immune responses. Nat. Immunol. 12, 5–9 (2011).

  23. 23.

    , , , & Human nutrition, the gut microbiome and the immune system. Nature 474, 327–336 (2011).

  24. 24.

    et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl Acad. Sci. USA 107, 14691–14696 (2010).

  25. 25.

    et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559–563 (2014).

  26. 26.

    et al. Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. USA 102, 11070–11075 (2005).

  27. 27.

    & Looking for a signal in the noise: revisiting obesity and the microbiome. mBio 7, e01018-16 (2016).

  28. 28.

    , , , & Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28, 1221–1227 (1987).

  29. 29.

    et al. The role of short-chain fatty acids in health and disease. Adv. Immunol. 121, 91–119 (2014).

  30. 30.

    & Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis. Gut 37, 684–689 (1995).

  31. 31.

    & Dietary effects on human gut microbiome diversity. Br. J. Nutr. 113 (Suppl.), S1–S5 (2015).

  32. 32.

    et al. Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519, 92–96 (2015).

  33. 33.

    et al. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature 514, 181–186 (2014).

  34. 34.

    et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc. Natl Acad. Sci. USA 107, 11971–11975 (2010).

  35. 35.

    , , , & Animal antibiotic use has an early but important impact on the emergence of antibiotic resistance in human commensal bacteria. Proc. Natl Acad. Sci. USA 99, 6434–6439 (2002).

  36. 36.

    et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut 63, 1913–1920 (2014).

  37. 37.

    et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013).

  38. 38.

    et al. Human genetics shape the gut microbiome. Cell 159, 789–799 (2014).

  39. 39.

    et al. Shotgun metagenomics of 250 adult twins reveals genetic and environmental impacts on the gut microbiome. Cell Syst. 3, 572–584.e3 (2016).

  40. 40.

    et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J. 4, 232–241 (2010).

  41. 41.

    et al. Immune mechanisms in arterial hypertension. J. Am. Soc. Nephrol. 27, 677–686 (2016).

  42. 42.

    T lymphocytes: a role in hypertension? Curr. Opin. Nephrol. Hypertens. 19, 181–186 (2010).

  43. 43.

    et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337–349 (2008).

  44. 44.

    et al. Influence of intestinal bacteria on induction of regulatory T cells: lessons from a transfer model of colitis. Gut 54, 1546–1552 (2005).

  45. 45.

    , , & An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122, 107–118 (2005).

  46. 46.

    et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 31, 677–689 (2009).

  47. 47.

    et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. BMJ 349, g4490 (2014).

  48. 48.

    et al. Relation of vegetable, fruit, and meat intake to 7-year blood pressure change in middle-aged men: the Chicago Western Electric Study. Am. J. Epidemiol. 159, 572–580 (2004).

  49. 49.

    et al. Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 27, 1065–1072 (1996).

  50. 50.

    et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N. Engl. J. Med. 336, 1117–1124 (1997).

  51. 51.

    , , , & The effect of the Mediterranean diet on hypertension: a systematic review and meta-analysis. J. Nutr. Educ. Behav. 48, 42–53.e1 (2016).

  52. 52.

    et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 368, 1279–1290 (2013).

  53. 53.

    et al. Fruit and vegetable consumption is inversely associated with blood pressure in a Mediterranean population with a high vegetable-fat intake: the Seguimiento Universidad de Navarra (SUN) Study. Br. J. Nutr. 92, 311–319 (2004).

  54. 54.

    et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 347, f6879 (2013).

  55. 55.

    Australian Bureau of Statistics. 4364.0.55.007 – Australian Health Survey: Nutrition First Results – Food and Nutrients, 2011–12. (2014).

  56. 56.

    , & Trends in dietary fiber intake in the United States, 1999–2008. J. Acad. Nutr. Diet. 112, 642–648 (2012).

  57. 57.

    , , & Dietary fiber intake and mortality in the NIH-AARP diet and health study. Arch. Intern. Med. 171, 1061–1068 (2011).

  58. 58.

    et al. Effect of dietary fiber intake on blood pressure: a meta-analysis of randomized, controlled clinical trials. J. Hypertens. 23, 475–481 (2005).

  59. 59.

    , , , & Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch. Intern. Med. 165, 150–156 (2005).

  60. 60.

    et al. Total, insoluble and soluble dietary fibre intake in relation to blood pressure: the INTERMAP Study. Br. J. Nutr. 114, 1480–1486 (2015).

  61. 61.

    & Effects of dietary fiber and its components on metabolic health. Nutrients 2, 1266–1289 (2010).

  62. 62.

    & Fiber and cardiovascular disease risk: how strong is the evidence? J. Cardiovasc. Nurs. 21, 3–8 (2006).

  63. 63.

    & Tone and reactivity of vascular smooth muscle in germfree rat mesentery. J. Exp. Med. 134, 846–856 (1971).

  64. 64.

    , & Effects of microbial flora on cardiac output and other elements of blood circulation. Proc. Soc. Exp. Biol. Med. 114, 301–304 (1963).

  65. 65.

    Response of germfree animals to shock. J. Med. 21, 51–66 (1990).

  66. 66.

    et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol. Genomics 47, 187–197 (2015).

  67. 67.

    et al. Alterations in the gut microbiota can elicit hypertension in rats. Physiol. Genomics 49, 96–104 (2017).

  68. 68.

    et al. Gut dysbiosis is linked to hypertension. Hypertension 65, 1331–1340 (2015).

  69. 69.

    et al. Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension 67, 469–474 (2016).

  70. 70.

    et al. Exercise induction of gut microbiota modifications in obese, non-obese and hypertensive rats. BMC Genomics 15, 511 (2014).

  71. 71.

    , & Genetic architecture of Wistar-Kyoto rat and spontaneously hypertensive rat substrains from different sources. Physiol. Genomics 45, 528–538 (2013).

  72. 72.

    et al. Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice. Mucosal Immunol. 10, 104–116 (2017).

  73. 73.

    et al. Brain microglial cytokines in neurogenic hypertension. Hypertension 56, 297–303 (2010).

  74. 74.

    et al. Gut microbiota promote angiotensin II-induced arterial hypertension and vascular dysfunction. J. Am. Heart Assoc. 5, e003698 (2016).

  75. 75.

    et al. Hypertension-linked pathophysiological alterations in the gut. Circ. Res. 120, 312–323 (2017).

  76. 76.

    et al. Hypertension-linked mechanical changes of rat gut. Acta Biomater. 45, 296–302 (2016).

  77. 77.

    , & The sympathetic nervous system alterations in human hypertension. Circ. Res. 116, 976–990 (2015).

  78. 78.

    , , & The gut–brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann. Gastroenterol. 28, 203–209 (2015).

  79. 79.

    & A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. J. Hum. Hypertens. 23, 363–384 (2009).

  80. 80.

    Salt and water absorption in the human colon: a modern appraisal. Gut 43, 294–299 (1998).

  81. 81.

    et al. Antihypertensive and laxative effects by pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut. Hypertension 60, 1560–1567 (2012).

  82. 82.

    , , , & Gut hormones and gut microbiota: implications for kidney function and hypertension. J. Am. Soc. Hypertens. 10, 954–961 (2016).

  83. 83.

    US National Library of Medicine. ClinicalTrials.gov (2016).

  84. 84.

    US National Library of Medicine. ClinicalTrials.gov (2017).

  85. 85.

    et al. Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 5, 14 (2017).

  86. 86.

    , & Porphyromonas gingivalis: an overview of periodontopathic pathogen below the gum line. Front. Microbiol. 7, 53 (2016).

  87. 87.

    et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect. Drug Resist. 7, 183–197 (2014).

  88. 88.

    et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect. Dis. 13, 785–796 (2013).

  89. 89.

    et al. A nested case-control study of association between metabolome and hypertension risk. Biomed Res. Int. 2016, 7646979 (2016).

  90. 90.

    & Acetate relaxation of isolated vascular smooth muscle. Kidney Int. 32, 39–46 (1987).

  91. 91.

    , & Vasorelaxant effects of short chain fatty acid salts in rat caudal artery. Am. J. Physiol. 261, H561–H567 (1991).

  92. 92.

    , , & Short chain fatty acids dilate isolated human colonic resistance arteries. Gut 31, 1391–1394 (1990).

  93. 93.

    et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc. Natl Acad. Sci. USA 110, 4410–4415 (2013).

  94. 94.

    et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion. J. Am. Soc. Nephrol. 26, 1877–1888 (2015).

  95. 95.

    , , , & Metabolite-sensing G protein-coupled receptors-facilitators of diet-related immune regulation. Annu. Rev. Immunol. 35, 371–402 (2017).

  96. 96.

    et al. Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 6, 6734 (2015).

  97. 97.

    et al. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G-protein coupled receptor 41. Physiol. Genomics 48, 826–834 (2016).

  98. 98.

    et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat. Immunol. 18, 552–562 (2017).

  99. 99.

    , & GPR109A and vascular inflammation. Curr. Atheroscler. Rep. 15, 325 (2013).

  100. 100.

    et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 16, 544–550 (2010).

  101. 101.

    et al. Salt-sensitive hypertension is associated with dysfunctional Cyp4a10 gene and kidney epithelial sodium channel. J. Clin. Invest. 116, 1696–1702 (2006).

  102. 102.

    et al. Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin. Diabetes 61, 897–907 (2012).

  103. 103.

    et al. Telethonin deficiency is associated with maladaptation to biomechanical stress in the mammalian heart. Circ. Res. 109, 758–769 (2011).

  104. 104.

    et al. Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J. Biol. Chem. 285, 24487–24493 (2010).

  105. 105.

    Early growth response-1 in cardiovascular pathobiology. Circ. Res. 98, 186–191 (2006).

  106. 106.

    et al. Egr-1 deficiency protects from renal inflammation and fibrosis. J. Mol. Med. (Berl.) 94, 933–942 (2016).

  107. 107.

    et al. Attenuation of inflammatory response and reduction in infarct size by postconditioning are associated with downregulation of early growth response 1 during reperfusion in rat heart. Shock 41, 346–354 (2014).

  108. 108.

    et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).

  109. 109.

    et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576–585 (2013).

  110. 110.

    et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur. Heart J. 38, 814–824 (2017).

  111. 111.

    et al. Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can. J. Cardiol. 30, 1700–1705 (2014).

  112. 112.

    & Structure of bacterial lipopolysaccharides. Carbohydr. Res. 338, 2431–2447 (2003).

  113. 113.

    , & LPS/TLR4 signal transduction pathway. Cytokine 42, 145–151 (2008).

  114. 114.

    et al. Lung exposure to lipopolysaccharide causes atherosclerotic plaque destabilisation. Eur. Respir. J. 48, 205–215 (2016).

  115. 115.

    et al. Serum lipopolysaccharide-binding protein as a marker of atherosclerosis. Atherosclerosis 230, 223–227 (2013).

  116. 116.

    et al. Gut-derived serum lipopolysaccharide is associated with enhanced risk of major adverse cardiovascular events in atrial fibrillation: effect of adherence to Mediterranean diet. J. Am. Heart Assoc. 6, e005784 (2017).

  117. 117.

    & Cellular activation mechanisms in septic shock. Front. Biosci. 3, d468–d476 (1998).

  118. 118.

    et al. Effects of intraduodenal injection of Lactobacillus johnsonii La1 on renal sympathetic nerve activity and blood pressure in urethane-anesthetized rats. Neurosci. Lett. 389, 109–114 (2005).

  119. 119.

    et al. Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats. Mol. Nutr. Food Res. 59, 2326–2336 (2015).

  120. 120.

    et al. Long-term intake of milk peptides attenuates development of hypertension in spontaneously hypertensive rats. J. Physiol. Pharmacol. 52, 745–754 (2001).

  121. 121.

    , , & Antihypertensive effect of sour milk and peptides isolated from it that are inhibitors to angiotensin I-converting enzyme. J. Dairy Sci. 78, 1253–1257 (1995).

  122. 122.

    et al. Purification and characterization of angiotensin I-converting enzyme inhibitors from sour milk. J. Dairy Sci. 78, 777–783 (1995).

  123. 123.

    , & Antihypertensive effect of the peptides derived from casein by an extracellular proteinase from Lactobacillus helveticus CP790. J. Dairy Sci. 77, 917–922 (1994).

  124. 124.

    et al. Effect of probiotic fermented milk on blood pressure: a meta-analysis of randomised controlled trials. Br. J. Nutr. 110, 1188–1194 (2013).

  125. 125.

    , , & Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 64, 897–903 (2014).

  126. 126.

    et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 330, 831–835 (2010).

  127. 127.

    et al. Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341, 295–298 (2013).

  128. 128.

    , & Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am. J. Hypertens. 28, 355–361 (2015).

  129. 129.

    , , , & Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension — a case report. Int. J. Cardiol. 201, 157–158 (2015).

  130. 130.

    et al. Partial restoration of the microbiota of cesarean-born infants via vaginal microbial transfer. Nat. Med. 22, 250–253 (2016).

  131. 131.

    et al. Evolution of gut microbiota composition from birth to 24 weeks in the INFANTMET Cohort. Microbiome 5, 4 (2017).

  132. 132.

    et al. The long-term stability of the human gut microbiota. Science 341, 1237439 (2013).

  133. 133.

    & Maternal diet-induced obesity and offspring cardiovascular health. J. Dev. Orig. Health Dis. 4, 338–347 (2013).

  134. 134.

    Critical differences between two low protein diet protocols in the programming of hypertension in the rat. Int. J. Food Sci. Nutr. 51, 11–17 (2000).

  135. 135.

    , , , & Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension. Circ. Res. 100, 520–526 (2007).

  136. 136.

    & Intergenerational programming of impaired nephrogenesis and hypertension in rats following maternal protein restriction during pregnancy. Br. J. Nutr. 101, 1020–1030 (2009).

  137. 137.

    et al. Maternal diet during gestation and lactation modifies the severity of salt-induced hypertension and renal injury in Dahl salt-sensitive rats. Hypertension 65, 447–455 (2015).

  138. 138.

    et al. Lower protein-to-carbohydrate ratio in maternal diet is associated with higher childhood systolic blood pressure up to age four years. Nutrients 7, 3078–3093 (2015).

  139. 139.

    et al. Evidence of infant blood pressure programming by maternal nutrition during pregnancy: a prospective randomized controlled intervention study. J. Pediatr. 152, 79–84.e2 (2008).

  140. 140.

    et al. Prenatal stress-induced alterations in major physiological systems correlate with gut microbiota composition in adulthood. Psychoneuroendocrinology 60, 58–74 (2015).

  141. 141.

    et al. Increased systolic and diastolic blood pressure is associated with altered gut microbiota composition and butyrate production in early pregnancy. Hypertension 68, 974–981 (2016).

  142. 142.

    et al. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study. Am. J. Epidemiol. 174, 807–815 (2011).

  143. 143.

    et al. Human gut microbiome viewed across age and geography. Nature 486, 222–227 (2012).

  144. 144.

    , , , & Systematic review with meta-analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment. Pharmacol. Ther. 43, 445–457 (2016).

  145. 145.

    & Weight gain after fecal microbiota transplantation. Open Forum Infect. Dis. 2, ofv004 (2015).

  146. 146.

    US Food & Drug Administration. Draft guidance for industry: enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. (2016).

  147. 147.

    , & Oral microbiome and nitric oxide: the missing link in the management of blood pressure. Curr. Hypertens. Rep. 19, 33 (2017).

  148. 148.

    et al. Gut microbiome associates with lifetime cardiovascular disease risk profile among Bogalusa Heart Study participants. Circ. Res. 119, 956–964 (2016).

  149. 149.

    et al. Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study. PLoS ONE 8, e54461 (2013).

Download references

Acknowledgements

F.Z.M. is supported by a National Heart Foundation Future Leader Fellowship, and D.K. is supported by a National Health & Medical Research Council of Australia Fellowship.

Author information

Affiliations

  1. Heart Failure Research Group, Baker Heart and Diabetes Institute, 75 Commercial Road, Melbourne, Victoria 3004, Australia.

    • Francine Z. Marques
    •  & David M. Kaye
  2. Department of Pharmacology, Faculty of Medicine, Nursing and Health Sciences, Monash University, Wellington Road, Clayton Victoria 3800, Australia.

    • Francine Z. Marques
  3. Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, 23 Innovation Walk, Clayton, Victoria 3800, Australia.

    • Charles R. Mackay
  4. Heart Centre, Alfred Hospital, Philip Block, Level 3, 55 Commercial Road, Melbourne, Victoria 3004, Australia.

    • David M. Kaye
  5. Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, 99 Commercial Road, Melbourne, Victoria 3004, Australia.

    • David M. Kaye

Authors

  1. Search for Francine Z. Marques in:

  2. Search for Charles R. Mackay in:

  3. Search for David M. Kaye in:

Contributions

F.Z.M. and C.R.K. researched data for the article and wrote the article. All authors provided substantial contribution to discussion of the content, and reviewed and edited the manuscript before submission.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Francine Z. Marques.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrcardio.2017.120

Further reading